Latest & greatest articles for ezetimibe

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ezetimibe or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ezetimibe and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ezetimibe

41. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study

Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study Reckless J, Davies G, Tunceli K, Hu XH, Brudi P Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of switching to a combination of ezetimibe and simvastatin, compared with doubling the statin dose, for patients with acute coronary syndrome, who had

NHS Economic Evaluation Database.2010

42. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study) 19539078 2009 06 22 2009 07 14 2015 11 19 1879-1913 103 12 2009 Jun 15 The American journal of cardiology Am. J. Cardiol. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). 1694-702 10.1016/j.amjcard.2009.05.003 (...) Patients with the metabolic syndrome are at an increased risk of cardiovascular disease and might require intensive lipid therapy. Many patients remain at the starting dose of lipid therapy and might not be titrated up to a higher dose. The present double-blind, randomized, 6-week study assessed the lipid-lowering efficacy of ezetimibe/simvastatin 10/20 mg versus atorvastatin 10 or 20 mg, and ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in 1,128 patients with hypercholesterolemia and the

EvidenceUpdates2009

43. Effect on serum lipid levels of switching dose of ezetimibe from 10 to 5 mg

Effect on serum lipid levels of switching dose of ezetimibe from 10 to 5 mg 19463517 2009 05 25 2009 06 18 2015 11 19 1879-1913 103 11 2009 Jun 01 The American journal of cardiology Am. J. Cardiol. Effect on serum lipid levels of switching dose of ezetimibe from 10 to 5 mg. 1568-71 10.1016/j.amjcard.2009.01.365 Although during its initial development, lower doses of ezetimibe reduced low-density lipoprotein (LDL) significantly, ezetimibe is available only in 10-mg form. Compliant patients (...) receiving ezetimibe 10 mg were randomized in a blinded fashion to continue therapy with ezetimibe 10 mg or to convert to a split-tablet 5-mg dose. Lipid panels were collected at baseline and after 4 weeks of therapy. The impact of the 2 ezetimibe dosing strategies on LDL and the achievement of the Adult Treatment Panel III LDL goal was evaluated. One hundred thirty patients receiving ezetimibe 10 mg were screened for eligibility. Thirty-nine of the 130 patients were randomized; 36 patients successfully

EvidenceUpdates2009

44. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin

The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin 19295325 2009 03 19 2009 05 22 2015 11 19 1534-6080 87 5 2009 Mar 15 Transplantation Transplantation The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. 771-5 10.1097/TP.0b013e318198d7d0 Despite statin treatment, hyperlipidemia remains problematic after cardiac transplantation and is associated with the development of cardiac allograft vasculopathy (...) . The cholesterol absorption inhibitor ezetimibe may offer a viable option for add on therapy; however, questions have been raised regarding the safety of this during concomitant cyclosporin treatment. This is the first placebo controlled, randomized double blinded trial assessing the efficacy and tolerability of ezetimibe in cardiac transplant recipients receiving cyclosporin. Sixty-eight cardiac transplant patients were randomized to receive ezetimibe (10 mg) or matching placebo for 6 months in addition

EvidenceUpdates2009

45. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy

Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy 19166691 2009 01 26 2009 02 11 2015 11 19 1879-1913 103 3 2009 Feb 01 The American journal of cardiology Am. J. Cardiol. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy (...) . 369-74 10.1016/j.amjcard.2008.09.090 Inflammation is associated with coronary artery disease (CAD), and statins reduce the inflammatory marker C-reactive protein (CRP). The effects of ezetimibe, alone or in combination with statins, on CRP and low-density lipoprotein (LDL) cholesterol were examined in 2 pooled analyses of randomized, placebo-controlled trials of ezetimibe 10 mg/day in patients with hypercholesterolemia: 6 12-week trials as monotherapy (n = 1,372) and 7 6- to 8-week trials as add

EvidenceUpdates2009

46. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease 19026302 2008 11 25 2008 12 22 2015 11 19 1879-1913 102 11 2008 Dec 01 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary (...) heart disease. 1489-94 10.1016/j.amjcard.2008.09.075 The aim of this study was to evaluate the efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in patients with hypercholesterolemia at moderately high risk for coronary heart disease who did not reach low-density lipoprotein (LDL) cholesterol levels <100 mg/dl with atorvastatin 20 mg. In this 6-week, multicenter, double-blind, randomized, parallel-group study, 196 patients treated with atorvastatin 20

EvidenceUpdates2009

47. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease 19026303 2008 11 25 2008 12 22 2015 11 19 1879-1913 102 11 2008 Dec 01 The American journal of cardiology Am. J. Cardiol. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary (...) heart disease. 1495-501 10.1016/j.amjcard.2008.09.076 The percentage of change from baseline in low-density lipoprotein (LDL) cholesterol after the addition of ezetimibe 10 mg to atorvastatin 40 mg was compared with uptitration to atorvastatin 80 mg. In this multicenter, double-blind, parallel-group study, adult hypercholesterolemic patients using atorvastatin 40 mg/day were randomly assigned to atorvastatin 40 mg plus ezetimibe 10 mg or uptitration to atorvastatin 80 mg. After 6 weeks of treatment, compared

EvidenceUpdates2009

48. Extended-release niacin or ezetimibe and carotid intima-media thickness.

Extended-release niacin or ezetimibe and carotid intima-media thickness. 19915217 2009 11 26 2009 12 07 2016 11 25 1533-4406 361 22 2009 Nov 26 The New England journal of medicine N. Engl. J. Med. Extended-release niacin or ezetimibe and carotid intima-media thickness. 2113-22 10.1056/NEJMoa0907569 Treatment added to statin monotherapy to further modify the lipid profile may include combination therapy to either raise the high-density lipoprotein (HDL) cholesterol level or further lower (...) mg per day) or ezetimibe (10 mg per day). The primary end point was the between-group difference in the change from baseline in the mean common carotid intima-media thickness after 14 months. The trial was terminated early, on the basis of efficacy, according to a prespecified analysis conducted after 208 patients had completed the trial. The mean HDL cholesterol level in the niacin group increased by 18.4% over the 14-month study period, to 50 mg per deciliter (P < 0.001), and the mean

NEJM2009

49. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above

NIHR HTA programme2008

50. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials

Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials 18489938 2008 05 20 2008 07 15 2015 11 19 0002-9149 101 11 2008 Jun 01 The American journal of cardiology Am. J. Cardiol. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. 1606-13 10.1016/j.amjcard.2008.01.041 Effective treatment to achieve target lipid parameters in high-risk patients may require combination drug therapies. Concerns (...) regarding risks associated with such combination therapies may limit their use. A systematic overview of randomized controlled trials to assess risks associated with combination statin and ezetimibe therapy was performed. Eighteen trials were identified, including 14,471 patients. Follow-up ranged from 6 to 48 weeks. Compared with statin monotherapy, combination therapy did not result in significant absolute increases in risks of myalgias (risk difference -0.033, 95% confidence interval [CI] -0.06

EvidenceUpdates2008

51. Use of Ezetimibe in the United States and Canada.

Use of Ezetimibe in the United States and Canada. BACKGROUND: Ezetimibe lowers low-density lipoprotein cholesterol, but current lipid-lowering guidelines in the United States and Canada do not recommend it as a first option for either primary or secondary prevention. We sought to describe the adoption of ezetimibe relative to that of other lipid-lowering agents and compare its use in the two countries. METHODS: We conducted a population-level, cohort study using data from January 2002 (...) to December 2006, provided by IMS Health, to describe prescribing practices and expenditures for lipid-lowering agents and ezetimibe in the United States and Canada. RESULTS: From 2002 to 2006, the monthly number of prescriptions for lipid-lowering agents rose from 3719 to 7401 per 100,000 population in Canada and from 3927 to 6827 per 100,000 population in the United States. Of these prescriptions, the proportion for ezetimibe rose from 0.2% in 2003 to 3.4% in 2006 in Canada and from 0.1% in 2002 to 15.2

NEJM2008

52. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J CRD summary This well-conducted review concluded that ezetimibe alone or in combination with a statin was effective (...) in reducing low density lipoprotein cholesterol in short-term studies. When used alone, ezetimibe is less effective than statins. The authors' conclusions reflect the evidence and their recommendations for research appear appropriate given the lack of long-term data in the included studies. Authors' objectives To review the clinical and cost-effectiveness of ezetimibe for treatment of primary hypercholesterolaemia. Searching Twelve electronic databases were searched from inception to June 2006. Search

DARE.2008

53. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis

Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs (...) using data registries Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each

NHS Economic Evaluation Database.2008

54. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model

Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Rees A, Wilkinson A, Durrington P, Chilcott (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of long-term ezetimibe (EZE) monotherapy in comparison with no treatment in patients with established cardiovascular disease

NHS Economic Evaluation Database.2008

55. Ezetimibe for the treatment of adult patients with hypercholesterolemia

Ezetimibe for the treatment of adult patients with hypercholesterolemia Ezetimibe for the treatment of adult patients with hypercholesterolemia | Therapeutics Initiative Independent Healthcare Evidence > > Ezetimibe for the treatment of adult patients with hypercholesterolemia Background information of the condition Drug therapy reduces total cholesterol levels, but their benefit in terms of mortality and morbidity vary with different drug classes. Statins have been shown to provide (...) not been studied in any large secondary prevention trials. Drug (Product monograph) Category Ezetimibe is a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol and related plant sterols. Mechanism of action: Ezetimibe inhibits the intestinal absorption of cholesterol and related plant sterols. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol

Therapeutics Letter2008

56. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Southampton: NIHR Health Technology Assessment programme. Health Technology Assessment 2008; Vol.12: No.21. 2008 Authors' objectives To review the evidence for the clinical and cost-effectiveness of ezetimibe (in its licensed indication) as combination therapy

Health Technology Assessment (HTA) Database.2008

58. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. 18765433 2008 09 25 2008 09 30 2015 11 19 1533-4406 359 13 2008 Sep 25 The New England journal of medicine N. Engl. J. Med. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. 1343-56 10.1056/NEJMoa0804602 Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results. We conducted a randomized, double-blind trial (...) involving 1873 patients with mild-to-moderate, asymptomatic aortic stenosis. The patients received either 40 mg of simvastatin plus 10 mg of ezetimibe or placebo daily. The primary outcome was a composite of major cardiovascular events, including death from cardiovascular causes, aortic-valve replacement, nonfatal myocardial infarction, hospitalization for unstable angina pectoris, heart failure, coronary-artery bypass grafting, percutaneous coronary intervention, and nonhemorrhagic stroke. Secondary

NEJM2008

59. Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Simvastatin with or without ezetimibe in familial hypercholesterolemia. 18376000 2008 04 03 2008 04 10 2016 11 24 1533-4406 358 14 2008 Apr 03 The New England journal of medicine N. Engl. J. Med. Simvastatin with or without ezetimibe in familial hypercholesterolemia. 1431-43 10.1056/NEJMoa0800742 Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression (...) of atherosclerosis remains unknown. We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average

NEJM2008

60. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132) Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia | Guidance and guidelines | NICE Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia Technology appraisal guidance [TA132] Published date: 28 November 2007 Guidance . Explore Guidance app Copyright © 2017 National Institute for Health

National Institute for Health and Clinical Excellence - Technology Appraisals2007